机译:强度调制放射治疗的风险适应的早期生存效益在早期外鼻鼻腔型NK / T细胞淋巴瘤中的强度调节辐射治疗:多中心研究
Guizhou Med Univ Guizhou Canc Hosp Affiliated Hosp Dept Lymphoma Guiyang Guizhou Peoples R;
Chinese Acad Med Sci Natl Canc Ctr Canc Hosp State Key Lab Mol Oncol Beijing Peoples R China;
Hunan Canc Hosp Dept Radiat Oncol Changsha Hunan Peoples R China;
Fourth Mil Med Univ Xijing Hosp Dept Radiat Oncol Xian Shaanxi Peoples R China;
Acad Mil Med Sci Hosp 307 Dept Oncol Beijing Peoples R China;
Chongqing Canc Hosp &
Canc Inst Dept Radiat Oncol Chongqing Peoples R China;
Jiangsu Canc Hosp Dept Radiat Oncol Nanjing Jiangsu Peoples R China;
Tianjin Med Univ Canc Inst &
Hosp Natl Clin Res Ctr Canc Dept Radiat Oncol Tianjin Peoples R;
Tianjin Med Univ Canc Hosp Tianjin Peoples R China;
Huazhong Univ Sci &
Technol Tongji Med Coll Union Hosp Wuhan Hubei Peoples R China;
Huazhong Univ Sci &
Technol Tongji Med Coll Union Hosp Wuhan Hubei Peoples R China;
Chinese Peoples Liberat Army Gen Hosp Dept Radiat Oncol Beijing Peoples R China;
Anhui Med Univ Affiliated Prov Hosp Hefei Anhui Peoples R China;
Peking Union Med Coll Beijing Peoples R China;
Sun Yat Sen Univ Ctr Canc State Key Lab Oncol South China Collaborat Innovat Ctr Canc Med Dept;
Zhejiang Canc Hosp Dept Radiat Oncol Hangzhou Zhejiang Peoples R China;
Shanxi Canc Hosp Dept Radiat Oncol Taiyuan Peoples R China;
Shanxi Canc Hosp Dept Radiat Oncol Taiyuan Peoples R China;
Fujian Prov Canc Hosp Dept Radiat Oncol Fuzhou Fujian Peoples R China;
Chinese Acad Med Sci Natl Canc Ctr Canc Hosp State Key Lab Mol Oncol Beijing Peoples R China;
Chinese Acad Med Sci Natl Canc Ctr Canc Hosp Dept Radiat Oncol Beijing Peoples R China;
Peking Union Med Coll Beijing Peoples R China;
机译:强度调制放射治疗的风险适应的早期生存效益在早期外鼻鼻腔型NK / T细胞淋巴瘤中的强度调节辐射治疗:多中心研究
机译:在早期外鼻型NK / T细胞淋巴瘤中完全反应含天冬酰胺酶的化疗后完全反应,放射疗法是必不可少的:中国淋巴瘤协作组的多中心研究(CLCG)
机译:原发性肿瘤侵袭对现代化疗时代外鼻型NK / T细胞淋巴瘤治疗和存活的影响:中国淋巴瘤协作组的多中心研究(CLCG)
机译:在临床前动物模型中针对人类T淋巴细胞病毒1型成人T细胞淋巴瘤的靶向疗法的研究。
机译:基于烷淀戳酶的化疗和放射治疗的中间和高风险早期外鼻鼻型NK / T细胞淋巴瘤的远处转移随着远程转移而改善的整体生存结合随着远程转移而降低
机译:早期NKTCL在早期NKTCL中IMRT的风险适应性效益:中国淋巴瘤协作组的多中心研究